Theranostics Market Overview
The Theranostics Market is witnessing strong growth as healthcare systems increasingly combine advanced diagnostics with targeted treatment to deliver more personalized care. Theranostics integrates diagnostic testing, molecular imaging, biomarkers, and therapeutic approaches to identify disease characteristics and guide patient-specific treatment decisions. Growing adoption of personalized medicine, advances in molecular imaging and biomarker discovery, rising chronic disease prevalence, and increasing investment in targeted therapies are supporting market expansion. Oncology remains a major application area, while emerging opportunities in neurology, cardiology, infectious diseases, and autoimmune conditions are broadening the market.
As per MRFR analysis, the Theranostics Market size was estimated at USD 9.18 Billion in 2024. The market is projected to grow from USD 10.26 Billion in 2025 to USD 31.21 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.77% during the forecast period 2025–2035. North America held the largest regional market share in 2024, supported by advanced healthcare infrastructure, strong research investment, and favorable innovation conditions. Asia-Pacific is expected to remain an important growth region as healthcare infrastructure and precision-medicine adoption expand.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/8057
Key market players driving innovation and competitiveness in the Theranostics Market include:
Thermo Fisher Scientific (US)
Roche Diagnostics (CH)
Siemens Healthineers (DE)
Abbott Laboratories (US)
Bristol-Myers Squibb (US)
Merck KGaA (DE)
Illumina (US)
Genomic Health (US)
AstraZeneca (GB)
Novartis (CH)
The market is strongly supported by the shift toward personalized medicine and the growing ability to match diagnostic findings with targeted therapeutic strategies. Molecular imaging is an important technology segment because PET and other imaging approaches can help characterize disease and guide treatment. Biomarkers are also gaining momentum as clinicians and researchers seek reliable indicators of disease progression and treatment response. Hospitals represent the largest end-user segment, while diagnostic laboratories are becoming increasingly important as testing technologies and precision-medicine initiatives expand.
The Theranostics Market segmentation is structured across multiple dimensions. Based on Application Outlook, it includes Oncology, Neurology, Cardiology, Infectious Diseases, and Autoimmune Diseases. In terms of Technology Outlook, the market covers Molecular Imaging, Biomarkers, Genomics, Proteomics, and Metabolomics. The End User Outlook comprises Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, and Academic Institutions. Furthermore, by Product Type Outlook, the market includes Instruments, Reagents, and Software. Regionally, the market is analyzed across North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
Purchase the Complete Report for Strategic Insights and Market Forecasts:
https://www.marketresearchfuture.com/reports/theranostics-market-8057
The increasing integration of diagnostics and therapeutics is creating significant opportunities for pharmaceutical companies, diagnostic developers, imaging providers, and research institutions. Companion diagnostics, biomarker discovery, molecular imaging, and radiotheranostics are helping clinicians identify suitable patients and monitor treatment response. Collaboration between pharmaceutical and diagnostic companies is also accelerating development of integrated solutions, while regulatory adaptation and investment in personalized medicine are supporting wider adoption.
Recent Developments:
Roche continues to expand its theranostics capabilities, including diagnostic tools that support targeted treatment planning and precision oncology.
Novartis continues to advance radioligand therapy programs, strengthening the connection between molecular diagnosis and targeted radionuclide treatment.
Bristol-Myers Squibb has expanded research collaborations focused on novel biomarkers and therapeutic-response assessment.
Siemens Healthineers continues to advance molecular imaging technologies that support more precise diagnosis and treatment planning.
Genomic and biomarker technology companies are expanding testing capabilities to support patient selection and personalized treatment strategies.
Browse In-depth Market Research Report (Pages, Charts, Tables, Figures):
https://www.marketresearchfuture.com/reports/theranostics-market-8057
Reasons to Buy the Report:
Provides comprehensive insights into the Theranostics Market dynamics, trends, opportunities, and growth potential.
Helps identify emerging opportunities across oncology, neurology, cardiology, infectious diseases, and autoimmune conditions.
Offers detailed segmentation analysis across applications, technologies, end users, product types, and regions.
Includes competitive intelligence covering leading pharmaceutical, diagnostic, imaging, biotechnology, and healthcare technology companies.
Assists investors and stakeholders in making informed decisions supported by market forecasts, technology trends, competitive developments, and regional analysis.
Future Outlook:
The future of the Theranostics Market will be shaped by continued advances in personalized medicine, molecular imaging, biomarkers, genomics, and targeted therapies. Oncology is expected to remain the dominant application, while neurology and other disease areas may provide additional growth opportunities as biomarker-guided treatment becomes more established. Greater integration of artificial intelligence in diagnostics, companion diagnostics, and radiotheranostic approaches should further improve patient selection and treatment monitoring. With continued research, collaboration, and investment, the global Theranostics Market is projected to reach USD 31.21 Billion by 2035 at a CAGR of 11.77%.
➤➤Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
Radiopharmaceutical Theranostics Market
